Eric Venker Sells 20,727 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Key Points

• CEO Eric Venker sold 20,727 shares of Roivant Sciences on October 13th for approximately $336,814, reducing his overall stake by 1.36% to 1,504,959 shares.
• Roivant Sciences stock rose by 1.2% to $16.40, with a market cap of $11.20 billion and recent trading volume of 5,174,761 shares.
• Several brokerages have recently increased their price targets for Roivant Sciences, with a consensus target price of $19.94 and a rating of "Moderate Buy."

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 20,727 shares of Roivant Sciences stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $16.25, for a total transaction of $336,813.75. Following the completion of the sale, the chief executive officer owned 1,504,959 shares of the company's stock, valued at $24,455,583.75. This trade represents a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total transaction of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total transaction of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total transaction of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total transaction of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total transaction of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The shares were sold at an average price of $14.99, for a total transaction of $6,238,568.18.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The stock was sold at an average price of $14.95, for a total transaction of $10,223,079.10.
• On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00.
• On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.52, for a total transaction of $1,152,000.00.

Roivant Sciences Stock Up 1.2%

NASDAQ ROIV traded up $0.19 during midday trading on Tuesday, hitting $16.40. The company had a trading volume of 5,174,761 shares, compared to its average volume of 8,527,116. The firm has a fifty day simple moving average of $13.64 and a two-hundred day simple moving average of $11.87. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of -23.43 and a beta of 1.20. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $16.79.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock worth $66,000 after buying an additional 2,945 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Roivant Sciences in the first quarter valued at approximately $570,000. Fifth Third Bancorp raised its position in shares of Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after acquiring an additional 1,905 shares in the last quarter. Penn Davis Mcfarland Inc. grew its stake in Roivant Sciences by 3.5% during the 1st quarter. Penn Davis Mcfarland Inc. now owns 1,707,232 shares of the company's stock worth $17,226,000 after buying an additional 58,206 shares during the last quarter. Finally, GF Fund Management CO. LTD. grew its stake in shares of Roivant Sciences by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 18,641 shares of the company's stock valued at $188,000 after purchasing an additional 3,356 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ROIV. Jefferies Financial Group boosted their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, September 18th. HC Wainwright raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a report on Thursday, September 18th. Weiss Ratings reissued a "sell (d+)" rating on shares of Roivant Sciences in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Thursday, September 18th. Finally, Bank of America lifted their target price on Roivant Sciences from $12.00 to $16.50 and gave the stock a "neutral" rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.94.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.